LIPOCINE INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
LIPOCINE INC. (LPCN) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.89% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-03-10
- LIPOCINE INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-03-31 was 4.32%, a 10.49% increase year-over-year.
- LIPOCINE INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 3.91%, a 177.30% increase year-over-year.
- LIPOCINE INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-03-31 was 1.41%, a 200.00% increase year-over-year.
- LIPOCINE INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2021-03-31 was 0.47%, a 68.67% decline year-over-year.
- LIPOCINE INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 3.89%, a 11.79% decline from fiscal 2024.
- LIPOCINE INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.41%, a 18.23% increase from fiscal 2023.
- LIPOCINE INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.73%, a 21.90% increase from fiscal 2022.
- LIPOCINE INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 3.06%, a 194.23% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | 3.89% 10-K · filed 2026-03-10 | ||||
| 2024-12-31 | 4.41% 10-K · filed 2026-03-10 | ||||
| 2024-03-31 | 4.32% 10-Q · filed 2024-05-09 | ||||
| 2023-12-31 | 3.73% 10-K · filed 2025-03-13 | ||||
| 2023-09-30 | 3.73% 10-Q · filed 2023-11-08 | ||||
| 2023-06-30 | 3.73% 10-Q · filed 2023-08-10 | ||||
| 2023-03-31 | 3.91% 10-Q · filed 2024-05-09 | ||||
| 2022-12-31 | 3.06% 10-K · filed 2024-03-07 | ||||
| 2022-09-30 | 1.98% 10-Q · filed 2023-11-08 | ||||
| 2022-06-30 | 1.93% 10-Q · filed 2023-08-10 | ||||
| 2022-03-31 | 1.41% 10-Q · filed 2023-05-11 | ||||
| 2021-12-31 | 1.04% 10-K · filed 2023-03-10 | ||||
| 2021-09-30 | 0.52% 10-Q · filed 2022-11-09 | 53.56% 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | 0.52% 10-Q · filed 2022-08-08 | ||||
| 2021-03-31 | 0.47% 10-Q · filed 2022-05-09 | ||||
| 2020-12-31 | 0.93% 10-K · filed 2022-03-09 | ||||
| 2020-09-30 | 1.33% 10-Q · filed 2021-11-10 | ||||
| 2020-06-30 | 1.33% 10-Q · filed 2021-08-05 | ||||
| 2020-03-31 | 1.50% 10-Q · filed 2021-05-06 | ||||
| 2019-12-31 | 1.82% 10-K · filed 2021-03-11 | ||||
| 2019-09-30 | 1.82% 10-Q · filed 2020-11-10 | ||||
| 2019-06-30 | 1.90% 10-Q · filed 2020-08-06 | ||||
| 2018-12-31 | 2.80% 10-K · filed 2020-03-13 | ||||
| 2018-09-30 | 2.72% 10-Q · filed 2019-11-12 | ||||
| 2018-06-30 | 2.70% 10-Q · filed 2019-08-07 | ||||
| 2017-12-31 | 2.13% 10-K · filed 2019-03-06 | ||||
| 2017-09-30 | 1.96% 10-Q · filed 2018-11-07 | ||||
| 2017-06-30 | 1.96% 10-Q · filed 2018-08-07 | ||||
| 2017-03-31 | 1.73% 10-Q · filed 2017-05-08 | ||||
| 2016-12-31 | 1.76% 10-K · filed 2019-03-06 | ||||
| 2016-09-30 | 1.68% 10-Q · filed 2017-11-08 | ||||
| 2016-06-30 | 1.68% 10-Q · filed 2017-08-07 | ||||
| 2016-03-31 | 1.73% 10-Q · filed 2016-05-09 | ||||
| 2015-12-31 | 1.63% 10-K · filed 2018-03-12 | ||||
| 2015-09-30 | 1.66% 10-Q · filed 2016-11-08 | 1.63% 10-Q · filed 2015-11-12 | |||
| 2015-06-30 | 1.66% 10-Q · filed 2016-08-09 | ||||
| 2015-03-31 | 2.03% 10-Q · filed 2015-05-07 | ||||
| 2014-12-31 | 1.75% 10-K · filed 2017-03-06 | ||||
| 2014-09-30 | 1.75% 10-Q · filed 2015-11-12 | ||||
| 2014-06-30 | 1.93% 10-Q · filed 2015-08-11 | ||||
| 2014-03-31 | 2.03% 10-Q · filed 2014-05-13 | ||||
| 2013-12-31 | 1.38% 10-K · filed 2015-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |